Stifel Maintains Hold on Immunome, Lowers Price Target to $23
Benzinga Newsdesk 4 hours ago
Analyst RatingsNewsPrice Target
Stifel analyst Dara Azar maintains Immunome (NASDAQ:IMNM) with a Hold and lowers the price target from $24 to $23.
Stifel analyst Dara Azar maintains Immunome (NASDAQ:IMNM) with a Hold and lowers the price target from $24 to $23.